TY - JOUR
T1 - One target, different effects
T2 - A comparison of distinct therapeutic antibodies against the same targets
AU - Shim, Hyunbo
PY - 2011/10/31
Y1 - 2011/10/31
N2 - To date, more than 30 antibodies have been approved worldwide for therapeutic use. While the monoclonal antibody market is rapidly growing, the clinical use of therapeutic antibodies is mostly limited to treatment of cancers and immunological disorders. Moreover, antibodies against only five targets (TNF-α, HER2, CD20, EGFR, and VEGF) account for more than 80 percent of the worldwide market of therapeutic antibodies. The shortage of novel, clinically proven targets has resulted in the development of many distinct therapeutic antibodies against a small number of proven targets, based on the premise that different antibody molecules against the same target antigen have distinct biological and clinical effects from one another. For example, four antibodies against TNF-α have been approved by the FDA - infliximab, adalimumab, golimumab, and certolizumab pegol - with many more in clinical and preclinical development. The situation is similar for HER2, CD20, EGFR, and VEGF, each having one or more approved antibodies and many more under development. This review discusses the different binding characteristics, mechanisms of action, and biological and clinical activities of multiple monoclonal antibodies against TNF-α, HER-2, CD20, and EGFR and provides insights into the development of therapeutic antibodies.
AB - To date, more than 30 antibodies have been approved worldwide for therapeutic use. While the monoclonal antibody market is rapidly growing, the clinical use of therapeutic antibodies is mostly limited to treatment of cancers and immunological disorders. Moreover, antibodies against only five targets (TNF-α, HER2, CD20, EGFR, and VEGF) account for more than 80 percent of the worldwide market of therapeutic antibodies. The shortage of novel, clinically proven targets has resulted in the development of many distinct therapeutic antibodies against a small number of proven targets, based on the premise that different antibody molecules against the same target antigen have distinct biological and clinical effects from one another. For example, four antibodies against TNF-α have been approved by the FDA - infliximab, adalimumab, golimumab, and certolizumab pegol - with many more in clinical and preclinical development. The situation is similar for HER2, CD20, EGFR, and VEGF, each having one or more approved antibodies and many more under development. This review discusses the different binding characteristics, mechanisms of action, and biological and clinical activities of multiple monoclonal antibodies against TNF-α, HER-2, CD20, and EGFR and provides insights into the development of therapeutic antibodies.
KW - Antibodies
KW - Antigens
KW - CD20
KW - Epidermal growth factor
KW - Monoclonal
KW - Pharmacology
KW - Receptor
KW - Tumor necrosis factor-α
KW - erbB-2
UR - http://www.scopus.com/inward/record.url?scp=80055061034&partnerID=8YFLogxK
U2 - 10.3858/emm.2011.43.10.063
DO - 10.3858/emm.2011.43.10.063
M3 - Article
C2 - 21811090
AN - SCOPUS:80055061034
SN - 1226-3613
VL - 43
SP - 539
EP - 549
JO - Experimental and Molecular Medicine
JF - Experimental and Molecular Medicine
IS - 10
ER -